Identification of the possible therapeutic targets in the insulin-like growth factor 1 receptor pathway in a cohort of Egyptian hepatocellular carcinoma complicating chronic hepatitis C type 4
- PMID: 33132693
- PMCID: PMC7597224
- DOI: 10.33393/dti.2020.1548
Identification of the possible therapeutic targets in the insulin-like growth factor 1 receptor pathway in a cohort of Egyptian hepatocellular carcinoma complicating chronic hepatitis C type 4
Abstract
Background: Molecular targeted drugs are the first line of treatment of advanced hepatocellular carcinoma (HCC) due to its chemo- and radioresistant nature. HCC has several well-documented etiologic factors that drive hepatocarcinogenesis through different molecular pathways. Currently, hepatitis C virus (HCV) is a leading cause of HCC. Therefore, we included a unified cohort of HCV genotype 4-related HCCs to study the expression levels of genes involved in the insulin-like growth factor 1 receptor (IGF1R) pathway, which is known to be involved in all aspects of cancer growth and progression.
Aim: Determine the gene expression patterns of IGF1R pathway genes in a cohort of Egyptian HCV-related HCCs. Correlate them with different patient/tumor characteristics. Determine the activity status of involved pathways.
Methods: Total ribonucleic acid (RNA) was extracted from 32 formalin-fixed paraffin-embedded tissues of human HCV-related HCCs and 6 healthy liver donors as controls. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) using RT2 Profiler PCR Array for Human Insulin Signaling Pathway was done to determine significantly up- and downregulated genes with identification of most frequently coregulated genes, followed by correlation of gene expression with different patient/tumor characteristics. Finally, canonical pathway analysis was performed using the Ingenuity Pathway Analysis software.
Results: Six genes - AEBP1, AKT2, C-FOS, PIK3R1, PRKCI, SHC1 - were significantly overexpressed. Thirteen genes - ADRB3, CEBPA, DUSP14, ERCC1, FRS3, IGF2, INS, IRS1, JUN, MTOR, PIK3R2, PPP1CA, RPS6KA1 - were significantly underexpressed. Several differentially expressed genes were related to different tumor/patient characteristics. Nitric oxide and reactive oxygen species production pathway was significantly activated in the present cohort, while the growth hormone signaling pathway was inactive.
Conclusions: The gene expression patterns identified in this study may serve as possible therapeutic targets in HCV-related HCCs. The most frequently coregulated genes may serve to guide combined molecular targeted therapies. The IGF1R pathway showed evidence of inactivity in the present cohort of HCV-related HCCs, so targeting this pathway in therapy may not be effective.
Keywords: Gene expression; Hepatitis C virus; Hepatocellular carcinoma; Molecular therapeutic targets.
Copyright © 2020, The Authors.
Conflict of interest statement
Conflict of interest: All the authors declare no conflict of interest.
Figures




Similar articles
-
Detection of hepatitis C virus RNA using ligation-dependent polymerase chain reaction in formalin-fixed, paraffin-embedded liver tissues.Am J Pathol. 1996 Nov;149(5):1485-91. Am J Pathol. 1996. PMID: 8909238 Free PMC article.
-
Hepatitis C and B virus infections in hepatocellular carcinoma. Analysis of direct detection of viral genome in paraffin embedded tissues.Cancer. 1996 May 1;77(9):1787-91. doi: 10.1002/(SICI)1097-0142(19960501)77:9<1787::AID-CNCR5>3.0.CO;2-9. Cancer. 1996. PMID: 8646675
-
Overexpression of tumor-associated trypsin inhibitor (SPINK1/TATI) in hepatitis C-associated hepatocellular carcinoma: potential implications for viral hepatocarcinogenesis.Oncol Res Treat. 2014;37(12):732-8. doi: 10.1159/000369151. Epub 2014 Nov 21. Oncol Res Treat. 2014. PMID: 25531719
-
Hepatocarcinogenesis: hepatitis viruses and altered tumor suppressor gene function.Princess Takamatsu Symp. 1995;25:151-61. Princess Takamatsu Symp. 1995. PMID: 8875620 Review.
-
Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan.Princess Takamatsu Symp. 1995;25:27-32. Princess Takamatsu Symp. 1995. PMID: 8875606 Review.
Cited by
-
AEBP1 inhibition reduces cell growth and PI3K/AKT pathway while less regulates cell mobility in hepatocellular carcinoma.World J Surg Oncol. 2025 Mar 29;23(1):108. doi: 10.1186/s12957-025-03750-0. World J Surg Oncol. 2025. PMID: 40158165 Free PMC article.
References
-
- International Agency for Research on Cancer (IARC). Globocan. France: IARC; 2012. 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012.
-
- Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12(7):408–424. - PubMed
-
- El-zanaty F, Way A. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International; 2009. Egypt Demographic and Health Survey 2008.
-
- Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer. 2018;142(12):2471–7. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous